nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—ABCC4—Zidovudine—acquired immunodeficiency syndrome	0.0285	0.0577	CbGbCtD
Sunitinib—ABCC4—Lamivudine—acquired immunodeficiency syndrome	0.022	0.0446	CbGbCtD
Sunitinib—ABCC2—Indinavir—acquired immunodeficiency syndrome	0.0201	0.0408	CbGbCtD
Sunitinib—ABCC2—Saquinavir—acquired immunodeficiency syndrome	0.0177	0.0358	CbGbCtD
Sunitinib—ABCC2—Ritonavir—acquired immunodeficiency syndrome	0.0177	0.0358	CbGbCtD
Sunitinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0177	0.0358	CbGbCtD
Sunitinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.016	0.0324	CbGbCtD
Sunitinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.016	0.0324	CbGbCtD
Sunitinib—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0156	0.0315	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0156	0.0315	CbGbCtD
Sunitinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0153	0.031	CbGbCtD
Sunitinib—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0134	0.0272	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0134	0.0272	CbGbCtD
Sunitinib—ABCC2—Lamivudine—acquired immunodeficiency syndrome	0.0131	0.0265	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0131	0.0264	CbGbCtD
Sunitinib—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0131	0.0264	CbGbCtD
Sunitinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0129	0.0262	CbGbCtD
Sunitinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0119	0.024	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0118	0.0239	CbGbCtD
Sunitinib—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0118	0.0239	CbGbCtD
Sunitinib—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0118	0.0239	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0118	0.0239	CbGbCtD
Sunitinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0117	0.0237	CbGbCtD
Sunitinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0117	0.0237	CbGbCtD
Sunitinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0101	0.0204	CbGbCtD
Sunitinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.00979	0.0198	CbGbCtD
Sunitinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00886	0.0179	CbGbCtD
Sunitinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00886	0.0179	CbGbCtD
Sunitinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00841	0.017	CbGbCtD
Sunitinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00761	0.0154	CbGbCtD
Sunitinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00657	0.0133	CbGbCtD
Sunitinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00637	0.0129	CbGbCtD
Sunitinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00576	0.0117	CbGbCtD
Sunitinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00576	0.0117	CbGbCtD
Sunitinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00553	0.0112	CbGbCtD
Sunitinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00536	0.0108	CbGbCtD
Sunitinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00504	0.0102	CbGbCtD
Sunitinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00504	0.0102	CbGbCtD
Sunitinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00456	0.00922	CbGbCtD
Sunitinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00456	0.00922	CbGbCtD
Sunitinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00427	0.00865	CbGbCtD
Sunitinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00393	0.00796	CbGbCtD
Sunitinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00382	0.00773	CbGbCtD
Sunitinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00345	0.00699	CbGbCtD
Sunitinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00345	0.00699	CbGbCtD
Sunitinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00331	0.0067	CbGbCtD
Sunitinib—PRPF4—Indinavir—Nelfinavir—acquired immunodeficiency syndrome	0.00136	0.389	CbGdCrCtD
Sunitinib—PRPF4—Indinavir—Lopinavir—acquired immunodeficiency syndrome	0.00111	0.317	CbGdCrCtD
Sunitinib—PRPF4—Indinavir—Saquinavir—acquired immunodeficiency syndrome	0.00103	0.295	CbGdCrCtD
Sunitinib—YES1—blood—acquired immunodeficiency syndrome	0.000107	0.000642	CbGeAlD
Sunitinib—ULK3—central nervous system—acquired immunodeficiency syndrome	0.000107	0.000642	CbGeAlD
Sunitinib—MAP2K2—central nervous system—acquired immunodeficiency syndrome	0.000107	0.000642	CbGeAlD
Sunitinib—SLK—lung—acquired immunodeficiency syndrome	0.000107	0.000642	CbGeAlD
Sunitinib—ROCK1—brain—acquired immunodeficiency syndrome	0.000107	0.000641	CbGeAlD
Sunitinib—EPHB6—spinal cord—acquired immunodeficiency syndrome	0.000107	0.00064	CbGeAlD
Sunitinib—CLK2—lymph node—acquired immunodeficiency syndrome	0.000107	0.000639	CbGeAlD
Sunitinib—MAP3K2—central nervous system—acquired immunodeficiency syndrome	0.000107	0.000637	CbGeAlD
Sunitinib—STK10—blood—acquired immunodeficiency syndrome	0.000106	0.000636	CbGeAlD
Sunitinib—MAP4K2—lymph node—acquired immunodeficiency syndrome	0.000106	0.000636	CbGeAlD
Sunitinib—FGFR2—lung—acquired immunodeficiency syndrome	0.000106	0.000636	CbGeAlD
Sunitinib—TAOK3—blood—acquired immunodeficiency syndrome	0.000106	0.000634	CbGeAlD
Sunitinib—JAK2—lung—acquired immunodeficiency syndrome	0.000106	0.000632	CbGeAlD
Sunitinib—PDGFRA—blood—acquired immunodeficiency syndrome	0.000105	0.00063	CbGeAlD
Sunitinib—STK3—lymph node—acquired immunodeficiency syndrome	0.000105	0.000627	CbGeAlD
Sunitinib—DYRK1A—brain—acquired immunodeficiency syndrome	0.000105	0.000625	CbGeAlD
Sunitinib—TBK1—central nervous system—acquired immunodeficiency syndrome	0.000104	0.000624	CbGeAlD
Sunitinib—FYN—lung—acquired immunodeficiency syndrome	0.000104	0.000624	CbGeAlD
Sunitinib—RPS6KB1—nervous system—acquired immunodeficiency syndrome	0.000104	0.000624	CbGeAlD
Sunitinib—FLT1—vagina—acquired immunodeficiency syndrome	0.000104	0.000623	CbGeAlD
Sunitinib—YES1—bone marrow—acquired immunodeficiency syndrome	0.000104	0.000621	CbGeAlD
Sunitinib—TYK2—central nervous system—acquired immunodeficiency syndrome	0.000104	0.00062	CbGeAlD
Sunitinib—FGR—nervous system—acquired immunodeficiency syndrome	0.000104	0.00062	CbGeAlD
Sunitinib—RET—nervous system—acquired immunodeficiency syndrome	0.000104	0.00062	CbGeAlD
Sunitinib—YES1—spinal cord—acquired immunodeficiency syndrome	0.000103	0.000619	CbGeAlD
Sunitinib—AXL—nervous system—acquired immunodeficiency syndrome	0.000103	0.000617	CbGeAlD
Sunitinib—EPHB6—vagina—acquired immunodeficiency syndrome	0.000103	0.000616	CbGeAlD
Sunitinib—STK10—bone marrow—acquired immunodeficiency syndrome	0.000103	0.000616	CbGeAlD
Sunitinib—TAOK3—bone marrow—acquired immunodeficiency syndrome	0.000103	0.000613	CbGeAlD
Sunitinib—TAOK3—spinal cord—acquired immunodeficiency syndrome	0.000102	0.000611	CbGeAlD
Sunitinib—MERTK—brain—acquired immunodeficiency syndrome	0.000102	0.00061	CbGeAlD
Sunitinib—MAP3K3—lung—acquired immunodeficiency syndrome	0.000102	0.00061	CbGeAlD
Sunitinib—MAP4K5—lung—acquired immunodeficiency syndrome	0.000102	0.00061	CbGeAlD
Sunitinib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.000102	0.000607	CbGeAlD
Sunitinib—KDR—lymphoid tissue—acquired immunodeficiency syndrome	0.000101	0.000604	CbGeAlD
Sunitinib—DYRK1A—lymph node—acquired immunodeficiency syndrome	0.000101	0.000604	CbGeAlD
Sunitinib—RPS6KB1—central nervous system—acquired immunodeficiency syndrome	0.0001	0.0006	CbGeAlD
Sunitinib—MAP4K4—brain—acquired immunodeficiency syndrome	0.0001	0.000599	CbGeAlD
Sunitinib—FGR—central nervous system—acquired immunodeficiency syndrome	9.98e-05	0.000597	CbGeAlD
Sunitinib—RET—central nervous system—acquired immunodeficiency syndrome	9.98e-05	0.000597	CbGeAlD
Sunitinib—KDR—digestive system—acquired immunodeficiency syndrome	9.98e-05	0.000597	CbGeAlD
Sunitinib—YES1—vagina—acquired immunodeficiency syndrome	9.96e-05	0.000595	CbGeAlD
Sunitinib—NUAK2—brain—acquired immunodeficiency syndrome	9.95e-05	0.000595	CbGeAlD
Sunitinib—AXL—central nervous system—acquired immunodeficiency syndrome	9.94e-05	0.000594	CbGeAlD
Sunitinib—MAP3K12—brain—acquired immunodeficiency syndrome	9.88e-05	0.000591	CbGeAlD
Sunitinib—STK10—vagina—acquired immunodeficiency syndrome	9.87e-05	0.00059	CbGeAlD
Sunitinib—MERTK—lymph node—acquired immunodeficiency syndrome	9.87e-05	0.00059	CbGeAlD
Sunitinib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	9.86e-05	0.000589	CbGeAlD
Sunitinib—FLT1—lung—acquired immunodeficiency syndrome	9.86e-05	0.000589	CbGeAlD
Sunitinib—FGFR2—nervous system—acquired immunodeficiency syndrome	9.85e-05	0.000589	CbGeAlD
Sunitinib—TAOK3—vagina—acquired immunodeficiency syndrome	9.83e-05	0.000588	CbGeAlD
Sunitinib—JAK2—nervous system—acquired immunodeficiency syndrome	9.8e-05	0.000586	CbGeAlD
Sunitinib—PDGFRA—vagina—acquired immunodeficiency syndrome	9.77e-05	0.000584	CbGeAlD
Sunitinib—RPS6KA3—brain—acquired immunodeficiency syndrome	9.74e-05	0.000583	CbGeAlD
Sunitinib—EPHB6—lung—acquired immunodeficiency syndrome	9.74e-05	0.000583	CbGeAlD
Sunitinib—CSF1R—digestive system—acquired immunodeficiency syndrome	9.74e-05	0.000582	CbGeAlD
Sunitinib—MAP4K4—lymph node—acquired immunodeficiency syndrome	9.68e-05	0.000579	CbGeAlD
Sunitinib—MAP2K1—brain—acquired immunodeficiency syndrome	9.68e-05	0.000579	CbGeAlD
Sunitinib—FYN—nervous system—acquired immunodeficiency syndrome	9.66e-05	0.000578	CbGeAlD
Sunitinib—NUAK2—lymph node—acquired immunodeficiency syndrome	9.61e-05	0.000575	CbGeAlD
Sunitinib—CSNK1A1—brain—acquired immunodeficiency syndrome	9.55e-05	0.000571	CbGeAlD
Sunitinib—FLT3—lymph node—acquired immunodeficiency syndrome	9.55e-05	0.000571	CbGeAlD
Sunitinib—MAP3K12—lymph node—acquired immunodeficiency syndrome	9.55e-05	0.000571	CbGeAlD
Sunitinib—KDR—blood—acquired immunodeficiency syndrome	9.51e-05	0.000568	CbGeAlD
Sunitinib—MAP2K5—blood—acquired immunodeficiency syndrome	9.51e-05	0.000568	CbGeAlD
Sunitinib—CLK1—brain—acquired immunodeficiency syndrome	9.49e-05	0.000568	CbGeAlD
Sunitinib—FGFR2—central nervous system—acquired immunodeficiency syndrome	9.48e-05	0.000567	CbGeAlD
Sunitinib—MAP3K3—nervous system—acquired immunodeficiency syndrome	9.44e-05	0.000565	CbGeAlD
Sunitinib—MAP4K5—nervous system—acquired immunodeficiency syndrome	9.44e-05	0.000565	CbGeAlD
Sunitinib—JAK2—central nervous system—acquired immunodeficiency syndrome	9.43e-05	0.000564	CbGeAlD
Sunitinib—YES1—lung—acquired immunodeficiency syndrome	9.42e-05	0.000563	CbGeAlD
Sunitinib—RPS6KA3—lymph node—acquired immunodeficiency syndrome	9.42e-05	0.000563	CbGeAlD
Sunitinib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	9.36e-05	0.000429	CcSEcCtD
Sunitinib—MAP2K1—lymph node—acquired immunodeficiency syndrome	9.35e-05	0.000559	CbGeAlD
Sunitinib—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	9.33e-05	0.000428	CcSEcCtD
Sunitinib—STK10—lung—acquired immunodeficiency syndrome	9.33e-05	0.000558	CbGeAlD
Sunitinib—CAMK2G—brain—acquired immunodeficiency syndrome	9.32e-05	0.000557	CbGeAlD
Sunitinib—BMP2K—brain—acquired immunodeficiency syndrome	9.32e-05	0.000557	CbGeAlD
Sunitinib—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	9.3e-05	0.000427	CcSEcCtD
Sunitinib—FYN—central nervous system—acquired immunodeficiency syndrome	9.3e-05	0.000556	CbGeAlD
Sunitinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	9.3e-05	0.000427	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	9.3e-05	0.000427	CcSEcCtD
Sunitinib—TAOK3—lung—acquired immunodeficiency syndrome	9.3e-05	0.000556	CbGeAlD
Sunitinib—Back pain—Lamivudine—acquired immunodeficiency syndrome	9.29e-05	0.000426	CcSEcCtD
Sunitinib—CSF1R—blood—acquired immunodeficiency syndrome	9.28e-05	0.000555	CbGeAlD
Sunitinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	9.25e-05	0.000425	CcSEcCtD
Sunitinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	9.25e-05	0.000424	CcSEcCtD
Sunitinib—PDGFRA—lung—acquired immunodeficiency syndrome	9.24e-05	0.000552	CbGeAlD
Sunitinib—LRRK2—brain—acquired immunodeficiency syndrome	9.23e-05	0.000552	CbGeAlD
Sunitinib—Insomnia—Indinavir—acquired immunodeficiency syndrome	9.23e-05	0.000424	CcSEcCtD
Sunitinib—CSNK1A1—lymph node—acquired immunodeficiency syndrome	9.23e-05	0.000552	CbGeAlD
Sunitinib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	9.23e-05	0.000423	CcSEcCtD
Sunitinib—Oedema—Delavirdine—acquired immunodeficiency syndrome	9.23e-05	0.000423	CcSEcCtD
Sunitinib—KDR—bone marrow—acquired immunodeficiency syndrome	9.2e-05	0.00055	CbGeAlD
Sunitinib—Anorexia—Efavirenz—acquired immunodeficiency syndrome	9.19e-05	0.000422	CcSEcCtD
Sunitinib—CLK1—lymph node—acquired immunodeficiency syndrome	9.17e-05	0.000548	CbGeAlD
Sunitinib—Rash—Didanosine—acquired immunodeficiency syndrome	9.17e-05	0.000421	CcSEcCtD
Sunitinib—Infection—Delavirdine—acquired immunodeficiency syndrome	9.17e-05	0.000421	CcSEcCtD
Sunitinib—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	9.17e-05	0.000421	CcSEcCtD
Sunitinib—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	9.17e-05	0.000421	CcSEcCtD
Sunitinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	9.16e-05	0.00042	CcSEcCtD
Sunitinib—KDR—spinal cord—acquired immunodeficiency syndrome	9.16e-05	0.000548	CbGeAlD
Sunitinib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	9.16e-05	0.000548	CbGeAlD
Sunitinib—FLT1—nervous system—acquired immunodeficiency syndrome	9.13e-05	0.000546	CbGeAlD
Sunitinib—Cough—Ritonavir—acquired immunodeficiency syndrome	9.12e-05	0.000419	CcSEcCtD
Sunitinib—Headache—Didanosine—acquired immunodeficiency syndrome	9.11e-05	0.000418	CcSEcCtD
Sunitinib—PRKAA1—brain—acquired immunodeficiency syndrome	9.1e-05	0.000544	CbGeAlD
Sunitinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	9.1e-05	0.000418	CcSEcCtD
Sunitinib—MAP3K3—central nervous system—acquired immunodeficiency syndrome	9.09e-05	0.000544	CbGeAlD
Sunitinib—MAP4K5—central nervous system—acquired immunodeficiency syndrome	9.09e-05	0.000544	CbGeAlD
Sunitinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	9.09e-05	0.000417	CcSEcCtD
Sunitinib—Shock—Delavirdine—acquired immunodeficiency syndrome	9.08e-05	0.000417	CcSEcCtD
Sunitinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	9.06e-05	0.000416	CcSEcCtD
Sunitinib—Convulsion—Ritonavir—acquired immunodeficiency syndrome	9.06e-05	0.000416	CcSEcCtD
Sunitinib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	9.03e-05	0.000415	CcSEcCtD
Sunitinib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	9.03e-05	0.000414	CcSEcCtD
Sunitinib—EPHB6—nervous system—acquired immunodeficiency syndrome	9.02e-05	0.00054	CbGeAlD
Sunitinib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	9.01e-05	0.000413	CcSEcCtD
Sunitinib—CAMK2G—lymph node—acquired immunodeficiency syndrome	9e-05	0.000538	CbGeAlD
Sunitinib—BMP2K—lymph node—acquired immunodeficiency syndrome	9e-05	0.000538	CbGeAlD
Sunitinib—PTK2B—brain—acquired immunodeficiency syndrome	9e-05	0.000538	CbGeAlD
Sunitinib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	8.99e-05	0.000412	CcSEcCtD
Sunitinib—CSF1R—bone marrow—acquired immunodeficiency syndrome	8.98e-05	0.000537	CbGeAlD
Sunitinib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	8.97e-05	0.000412	CcSEcCtD
Sunitinib—FLT4—brain—acquired immunodeficiency syndrome	8.97e-05	0.000537	CbGeAlD
Sunitinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	8.96e-05	0.000411	CcSEcCtD
Sunitinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	8.96e-05	0.000411	CcSEcCtD
Sunitinib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	8.95e-05	0.000535	CbGeAlD
Sunitinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	8.95e-05	0.000411	CcSEcCtD
Sunitinib—CSF1R—spinal cord—acquired immunodeficiency syndrome	8.94e-05	0.000534	CbGeAlD
Sunitinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	8.93e-05	0.00041	CcSEcCtD
Sunitinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	8.93e-05	0.00041	CcSEcCtD
Sunitinib—LRRK2—lymph node—acquired immunodeficiency syndrome	8.92e-05	0.000533	CbGeAlD
Sunitinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000408	CcSEcCtD
Sunitinib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000408	CcSEcCtD
Sunitinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.000408	CcSEcCtD
Sunitinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	8.87e-05	0.000407	CcSEcCtD
Sunitinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	8.87e-05	0.000407	CcSEcCtD
Sunitinib—CSNK1E—brain—acquired immunodeficiency syndrome	8.85e-05	0.000529	CbGeAlD
Sunitinib—FGFR1—brain—acquired immunodeficiency syndrome	8.85e-05	0.000529	CbGeAlD
Sunitinib—KIT—digestive system—acquired immunodeficiency syndrome	8.84e-05	0.000529	CbGeAlD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	8.84e-05	0.000406	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	8.81e-05	0.000404	CcSEcCtD
Sunitinib—KDR—vagina—acquired immunodeficiency syndrome	8.81e-05	0.000527	CbGeAlD
Sunitinib—MAP2K5—vagina—acquired immunodeficiency syndrome	8.81e-05	0.000527	CbGeAlD
Sunitinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	8.8e-05	0.000404	CcSEcCtD
Sunitinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.8e-05	0.000404	CcSEcCtD
Sunitinib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	8.8e-05	0.000404	CcSEcCtD
Sunitinib—PRKAA1—lymph node—acquired immunodeficiency syndrome	8.79e-05	0.000526	CbGeAlD
Sunitinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	8.79e-05	0.000526	CbGeAlD
Sunitinib—FLT1—central nervous system—acquired immunodeficiency syndrome	8.79e-05	0.000525	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.79e-05	0.000403	CcSEcCtD
Sunitinib—Cough—Saquinavir—acquired immunodeficiency syndrome	8.78e-05	0.000403	CcSEcCtD
Sunitinib—Angioedema—Lamivudine—acquired immunodeficiency syndrome	8.77e-05	0.000402	CcSEcCtD
Sunitinib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	8.74e-05	0.000523	CbGeAlD
Sunitinib—Pain—Indinavir—acquired immunodeficiency syndrome	8.73e-05	0.0004	CcSEcCtD
Sunitinib—Constipation—Indinavir—acquired immunodeficiency syndrome	8.73e-05	0.0004	CcSEcCtD
Sunitinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	8.72e-05	0.0004	CcSEcCtD
Sunitinib—YES1—nervous system—acquired immunodeficiency syndrome	8.72e-05	0.000521	CbGeAlD
Sunitinib—Convulsion—Saquinavir—acquired immunodeficiency syndrome	8.72e-05	0.0004	CcSEcCtD
Sunitinib—IRAK4—brain—acquired immunodeficiency syndrome	8.72e-05	0.000521	CbGeAlD
Sunitinib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	8.71e-05	0.000399	CcSEcCtD
Sunitinib—PTK2B—lymph node—acquired immunodeficiency syndrome	8.69e-05	0.00052	CbGeAlD
Sunitinib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	8.69e-05	0.000399	CcSEcCtD
Sunitinib—EPHB6—central nervous system—acquired immunodeficiency syndrome	8.69e-05	0.000519	CbGeAlD
Sunitinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	8.68e-05	0.000398	CcSEcCtD
Sunitinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.68e-05	0.000398	CcSEcCtD
Sunitinib—FLT4—lymph node—acquired immunodeficiency syndrome	8.67e-05	0.000518	CbGeAlD
Sunitinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.67e-05	0.000398	CcSEcCtD
Sunitinib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	8.66e-05	0.000397	CcSEcCtD
Sunitinib—STK10—nervous system—acquired immunodeficiency syndrome	8.64e-05	0.000517	CbGeAlD
Sunitinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.64e-05	0.000396	CcSEcCtD
Sunitinib—Nausea—Didanosine—acquired immunodeficiency syndrome	8.64e-05	0.000396	CcSEcCtD
Sunitinib—PDGFRB—digestive system—acquired immunodeficiency syndrome	8.64e-05	0.000516	CbGeAlD
Sunitinib—TAOK3—nervous system—acquired immunodeficiency syndrome	8.61e-05	0.000515	CbGeAlD
Sunitinib—CSF1R—vagina—acquired immunodeficiency syndrome	8.6e-05	0.000514	CbGeAlD
Sunitinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	8.6e-05	0.000394	CcSEcCtD
Sunitinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	8.59e-05	0.000394	CcSEcCtD
Sunitinib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000393	CcSEcCtD
Sunitinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000393	CcSEcCtD
Sunitinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000393	CcSEcCtD
Sunitinib—CSNK1E—lymph node—acquired immunodeficiency syndrome	8.55e-05	0.000511	CbGeAlD
Sunitinib—FGFR1—lymph node—acquired immunodeficiency syndrome	8.55e-05	0.000511	CbGeAlD
Sunitinib—PDGFRA—nervous system—acquired immunodeficiency syndrome	8.55e-05	0.000511	CbGeAlD
Sunitinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	8.53e-05	0.000392	CcSEcCtD
Sunitinib—MAP2K2—brain—acquired immunodeficiency syndrome	8.52e-05	0.00051	CbGeAlD
Sunitinib—ULK3—brain—acquired immunodeficiency syndrome	8.52e-05	0.00051	CbGeAlD
Sunitinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.51e-05	0.000391	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.51e-05	0.00039	CcSEcCtD
Sunitinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	8.49e-05	0.000389	CcSEcCtD
Sunitinib—MAP3K2—brain—acquired immunodeficiency syndrome	8.46e-05	0.000506	CbGeAlD
Sunitinib—KIT—blood—acquired immunodeficiency syndrome	8.42e-05	0.000504	CbGeAlD
Sunitinib—IRAK4—lymph node—acquired immunodeficiency syndrome	8.42e-05	0.000503	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	8.41e-05	0.000386	CcSEcCtD
Sunitinib—YES1—central nervous system—acquired immunodeficiency syndrome	8.4e-05	0.000502	CbGeAlD
Sunitinib—Shock—Ritonavir—acquired immunodeficiency syndrome	8.4e-05	0.000385	CcSEcCtD
Sunitinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.38e-05	0.000385	CcSEcCtD
Sunitinib—MAP3K7—brain—acquired immunodeficiency syndrome	8.38e-05	0.000501	CbGeAlD
Sunitinib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.38e-05	0.000384	CcSEcCtD
Sunitinib—Cough—Lamivudine—acquired immunodeficiency syndrome	8.38e-05	0.000384	CcSEcCtD
Sunitinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.38e-05	0.000384	CcSEcCtD
Sunitinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.37e-05	0.000384	CcSEcCtD
Sunitinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.35e-05	0.000383	CcSEcCtD
Sunitinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.35e-05	0.000383	CcSEcCtD
Sunitinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	8.35e-05	0.000383	CcSEcCtD
Sunitinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	8.35e-05	0.000383	CcSEcCtD
Sunitinib—KDR—lung—acquired immunodeficiency syndrome	8.33e-05	0.000498	CbGeAlD
Sunitinib—MAP2K5—lung—acquired immunodeficiency syndrome	8.33e-05	0.000498	CbGeAlD
Sunitinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.33e-05	0.000382	CcSEcCtD
Sunitinib—STK10—central nervous system—acquired immunodeficiency syndrome	8.32e-05	0.000497	CbGeAlD
Sunitinib—Convulsion—Lamivudine—acquired immunodeficiency syndrome	8.32e-05	0.000382	CcSEcCtD
Sunitinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.32e-05	0.000382	CcSEcCtD
Sunitinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.31e-05	0.000381	CcSEcCtD
Sunitinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.29e-05	0.00038	CcSEcCtD
Sunitinib—TAOK3—central nervous system—acquired immunodeficiency syndrome	8.29e-05	0.000496	CbGeAlD
Sunitinib—TBK1—brain—acquired immunodeficiency syndrome	8.29e-05	0.000495	CbGeAlD
Sunitinib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	8.29e-05	0.00038	CcSEcCtD
Sunitinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.25e-05	0.000378	CcSEcCtD
Sunitinib—Pain—Efavirenz—acquired immunodeficiency syndrome	8.25e-05	0.000378	CcSEcCtD
Sunitinib—Rash—Nevirapine—acquired immunodeficiency syndrome	8.25e-05	0.000378	CcSEcCtD
Sunitinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.24e-05	0.000378	CcSEcCtD
Sunitinib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	8.24e-05	0.000492	CbGeAlD
Sunitinib—ULK3—lymph node—acquired immunodeficiency syndrome	8.23e-05	0.000492	CbGeAlD
Sunitinib—MAP2K2—lymph node—acquired immunodeficiency syndrome	8.23e-05	0.000492	CbGeAlD
Sunitinib—TYK2—brain—acquired immunodeficiency syndrome	8.23e-05	0.000492	CbGeAlD
Sunitinib—PDGFRB—blood—acquired immunodeficiency syndrome	8.23e-05	0.000492	CbGeAlD
Sunitinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	8.23e-05	0.000377	CcSEcCtD
Sunitinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.23e-05	0.000377	CcSEcCtD
Sunitinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	8.21e-05	0.000377	CcSEcCtD
Sunitinib—Headache—Nevirapine—acquired immunodeficiency syndrome	8.19e-05	0.000376	CcSEcCtD
Sunitinib—MAP3K2—lymph node—acquired immunodeficiency syndrome	8.18e-05	0.000489	CbGeAlD
Sunitinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.000375	CcSEcCtD
Sunitinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.000375	CcSEcCtD
Sunitinib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.000375	CcSEcCtD
Sunitinib—Infection—Saquinavir—acquired immunodeficiency syndrome	8.16e-05	0.000374	CcSEcCtD
Sunitinib—KIT—bone marrow—acquired immunodeficiency syndrome	8.15e-05	0.000487	CbGeAlD
Sunitinib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	8.13e-05	0.000373	CcSEcCtD
Sunitinib—CSF1R—lung—acquired immunodeficiency syndrome	8.13e-05	0.000486	CbGeAlD
Sunitinib—IRAK1—brain—acquired immunodeficiency syndrome	8.12e-05	0.000486	CbGeAlD
Sunitinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	8.12e-05	0.000373	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	8.12e-05	0.000372	CcSEcCtD
Sunitinib—KIT—spinal cord—acquired immunodeficiency syndrome	8.12e-05	0.000485	CbGeAlD
Sunitinib—MAP3K7—lymph node—acquired immunodeficiency syndrome	8.1e-05	0.000484	CbGeAlD
Sunitinib—Shock—Saquinavir—acquired immunodeficiency syndrome	8.08e-05	0.000371	CcSEcCtD
Sunitinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.07e-05	0.00037	CcSEcCtD
Sunitinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.07e-05	0.00037	CcSEcCtD
Sunitinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.05e-05	0.00037	CcSEcCtD
Sunitinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.05e-05	0.00037	CcSEcCtD
Sunitinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.04e-05	0.000369	CcSEcCtD
Sunitinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.03e-05	0.000368	CcSEcCtD
Sunitinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.02e-05	0.000368	CcSEcCtD
Sunitinib—TBK1—lymph node—acquired immunodeficiency syndrome	8.01e-05	0.000479	CbGeAlD
Sunitinib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	7.99e-05	0.000367	CcSEcCtD
Sunitinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	7.99e-05	0.000366	CcSEcCtD
Sunitinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	7.98e-05	0.000366	CcSEcCtD
Sunitinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	7.98e-05	0.000366	CcSEcCtD
Sunitinib—RPS6KB1—brain—acquired immunodeficiency syndrome	7.97e-05	0.000477	CbGeAlD
Sunitinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	7.97e-05	0.000366	CcSEcCtD
Sunitinib—Rash—Stavudine—acquired immunodeficiency syndrome	7.96e-05	0.000365	CcSEcCtD
Sunitinib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	7.96e-05	0.000476	CbGeAlD
Sunitinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	7.96e-05	0.000365	CcSEcCtD
Sunitinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	7.95e-05	0.000365	CcSEcCtD
Sunitinib—TYK2—lymph node—acquired immunodeficiency syndrome	7.95e-05	0.000475	CbGeAlD
Sunitinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	7.94e-05	0.000364	CcSEcCtD
Sunitinib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	7.93e-05	0.000474	CbGeAlD
Sunitinib—FGR—brain—acquired immunodeficiency syndrome	7.92e-05	0.000474	CbGeAlD
Sunitinib—RET—brain—acquired immunodeficiency syndrome	7.92e-05	0.000474	CbGeAlD
Sunitinib—Headache—Stavudine—acquired immunodeficiency syndrome	7.91e-05	0.000363	CcSEcCtD
Sunitinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	7.91e-05	0.000363	CcSEcCtD
Sunitinib—Pain—Delavirdine—acquired immunodeficiency syndrome	7.89e-05	0.000362	CcSEcCtD
Sunitinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	7.89e-05	0.000362	CcSEcCtD
Sunitinib—AXL—brain—acquired immunodeficiency syndrome	7.89e-05	0.000472	CbGeAlD
Sunitinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	7.89e-05	0.000362	CcSEcCtD
Sunitinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	7.87e-05	0.000361	CcSEcCtD
Sunitinib—IRAK1—lymph node—acquired immunodeficiency syndrome	7.85e-05	0.000469	CbGeAlD
Sunitinib—Rash—Abacavir—acquired immunodeficiency syndrome	7.84e-05	0.00036	CcSEcCtD
Sunitinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	7.84e-05	0.00036	CcSEcCtD
Sunitinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	7.84e-05	0.000359	CcSEcCtD
Sunitinib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	7.83e-05	0.000359	CcSEcCtD
Sunitinib—KIT—vagina—acquired immunodeficiency syndrome	7.81e-05	0.000467	CbGeAlD
Sunitinib—Headache—Abacavir—acquired immunodeficiency syndrome	7.79e-05	0.000358	CcSEcCtD
Sunitinib—Infection—Lamivudine—acquired immunodeficiency syndrome	7.78e-05	0.000357	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.77e-05	0.000357	CcSEcCtD
Sunitinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.77e-05	0.000356	CcSEcCtD
Sunitinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	7.77e-05	0.000356	CcSEcCtD
Sunitinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	7.72e-05	0.000354	CcSEcCtD
Sunitinib—KDR—nervous system—acquired immunodeficiency syndrome	7.72e-05	0.000461	CbGeAlD
Sunitinib—MAP2K5—nervous system—acquired immunodeficiency syndrome	7.72e-05	0.000461	CbGeAlD
Sunitinib—Shock—Lamivudine—acquired immunodeficiency syndrome	7.71e-05	0.000354	CcSEcCtD
Sunitinib—RPS6KB1—lymph node—acquired immunodeficiency syndrome	7.7e-05	0.000461	CbGeAlD
Sunitinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.68e-05	0.000353	CcSEcCtD
Sunitinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	7.67e-05	0.000352	CcSEcCtD
Sunitinib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	7.66e-05	0.000352	CcSEcCtD
Sunitinib—RET—lymph node—acquired immunodeficiency syndrome	7.66e-05	0.000458	CbGeAlD
Sunitinib—FGR—lymph node—acquired immunodeficiency syndrome	7.66e-05	0.000458	CbGeAlD
Sunitinib—PDGFRB—vagina—acquired immunodeficiency syndrome	7.63e-05	0.000456	CbGeAlD
Sunitinib—AXL—lymph node—acquired immunodeficiency syndrome	7.62e-05	0.000456	CbGeAlD
Sunitinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.62e-05	0.00035	CcSEcCtD
Sunitinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	7.62e-05	0.00035	CcSEcCtD
Sunitinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.61e-05	0.000349	CcSEcCtD
Sunitinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.61e-05	0.000349	CcSEcCtD
Sunitinib—SLK—brain—acquired immunodeficiency syndrome	7.6e-05	0.000454	CbGeAlD
Sunitinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.55e-05	0.000346	CcSEcCtD
Sunitinib—CSF1R—nervous system—acquired immunodeficiency syndrome	7.53e-05	0.00045	CbGeAlD
Sunitinib—FGFR2—brain—acquired immunodeficiency syndrome	7.53e-05	0.00045	CbGeAlD
Sunitinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.52e-05	0.000345	CcSEcCtD
Sunitinib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	7.52e-05	0.000345	CcSEcCtD
Sunitinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	7.51e-05	0.000345	CcSEcCtD
Sunitinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.51e-05	0.000345	CcSEcCtD
Sunitinib—Nausea—Stavudine—acquired immunodeficiency syndrome	7.5e-05	0.000344	CcSEcCtD
Sunitinib—JAK2—brain—acquired immunodeficiency syndrome	7.49e-05	0.000448	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.48e-05	0.000343	CcSEcCtD
Sunitinib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	7.47e-05	0.000343	CcSEcCtD
Sunitinib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	7.43e-05	0.000444	CbGeAlD
Sunitinib—KDR—central nervous system—acquired immunodeficiency syndrome	7.43e-05	0.000444	CbGeAlD
Sunitinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	7.43e-05	0.000341	CcSEcCtD
Sunitinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.42e-05	0.00034	CcSEcCtD
Sunitinib—Nausea—Abacavir—acquired immunodeficiency syndrome	7.39e-05	0.000339	CcSEcCtD
Sunitinib—FYN—brain—acquired immunodeficiency syndrome	7.39e-05	0.000442	CbGeAlD
Sunitinib—KIT—lung—acquired immunodeficiency syndrome	7.38e-05	0.000442	CbGeAlD
Sunitinib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	7.37e-05	0.000338	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.37e-05	0.000338	CcSEcCtD
Sunitinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.36e-05	0.000338	CcSEcCtD
Sunitinib—SLK—lymph node—acquired immunodeficiency syndrome	7.34e-05	0.000439	CbGeAlD
Sunitinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.32e-05	0.000336	CcSEcCtD
Sunitinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	7.32e-05	0.000336	CcSEcCtD
Sunitinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.3e-05	0.000335	CcSEcCtD
Sunitinib—Pain—Ritonavir—acquired immunodeficiency syndrome	7.3e-05	0.000335	CcSEcCtD
Sunitinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.29e-05	0.000335	CcSEcCtD
Sunitinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	7.29e-05	0.000335	CcSEcCtD
Sunitinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.26e-05	0.000333	CcSEcCtD
Sunitinib—CSF1R—central nervous system—acquired immunodeficiency syndrome	7.25e-05	0.000434	CbGeAlD
Sunitinib—JAK2—lymph node—acquired immunodeficiency syndrome	7.24e-05	0.000433	CbGeAlD
Sunitinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	7.23e-05	0.000332	CcSEcCtD
Sunitinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	7.22e-05	0.000331	CcSEcCtD
Sunitinib—MAP3K3—brain—acquired immunodeficiency syndrome	7.22e-05	0.000431	CbGeAlD
Sunitinib—MAP4K5—brain—acquired immunodeficiency syndrome	7.22e-05	0.000431	CbGeAlD
Sunitinib—PDGFRB—lung—acquired immunodeficiency syndrome	7.21e-05	0.000431	CbGeAlD
Sunitinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.14e-05	0.000328	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.14e-05	0.000328	CcSEcCtD
Sunitinib—FYN—lymph node—acquired immunodeficiency syndrome	7.14e-05	0.000427	CbGeAlD
Sunitinib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.11e-05	0.000326	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.09e-05	0.000325	CcSEcCtD
Sunitinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	7.09e-05	0.000325	CcSEcCtD
Sunitinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.08e-05	0.000325	CcSEcCtD
Sunitinib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	7.04e-05	0.000323	CcSEcCtD
Sunitinib—Pain—Saquinavir—acquired immunodeficiency syndrome	7.02e-05	0.000322	CcSEcCtD
Sunitinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.02e-05	0.000322	CcSEcCtD
Sunitinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	6.99e-05	0.00032	CcSEcCtD
Sunitinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6.98e-05	0.00032	CcSEcCtD
Sunitinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6.98e-05	0.00032	CcSEcCtD
Sunitinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	6.98e-05	0.00032	CcSEcCtD
Sunitinib—FLT1—brain—acquired immunodeficiency syndrome	6.98e-05	0.000417	CbGeAlD
Sunitinib—MAP3K3—lymph node—acquired immunodeficiency syndrome	6.97e-05	0.000417	CbGeAlD
Sunitinib—MAP4K5—lymph node—acquired immunodeficiency syndrome	6.97e-05	0.000417	CbGeAlD
Sunitinib—Rash—Zidovudine—acquired immunodeficiency syndrome	6.92e-05	0.000318	CcSEcCtD
Sunitinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	6.92e-05	0.000317	CcSEcCtD
Sunitinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	6.91e-05	0.000317	CcSEcCtD
Sunitinib—EPHB6—brain—acquired immunodeficiency syndrome	6.9e-05	0.000412	CbGeAlD
Sunitinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	6.9e-05	0.000316	CcSEcCtD
Sunitinib—ABCC4—digestive system—acquired immunodeficiency syndrome	6.88e-05	0.000411	CbGeAlD
Sunitinib—Headache—Zidovudine—acquired immunodeficiency syndrome	6.88e-05	0.000315	CcSEcCtD
Sunitinib—KIT—nervous system—acquired immunodeficiency syndrome	6.84e-05	0.000409	CbGeAlD
Sunitinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	6.82e-05	0.000313	CcSEcCtD
Sunitinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.81e-05	0.000312	CcSEcCtD
Sunitinib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	6.8e-05	0.000312	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.76e-05	0.00031	CcSEcCtD
Sunitinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.75e-05	0.00031	CcSEcCtD
Sunitinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.75e-05	0.00031	CcSEcCtD
Sunitinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000309	CcSEcCtD
Sunitinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000309	CcSEcCtD
Sunitinib—FLT1—lymph node—acquired immunodeficiency syndrome	6.74e-05	0.000403	CbGeAlD
Sunitinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	6.72e-05	0.000308	CcSEcCtD
Sunitinib—Pain—Lamivudine—acquired immunodeficiency syndrome	6.7e-05	0.000307	CcSEcCtD
Sunitinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.7e-05	0.000307	CcSEcCtD
Sunitinib—PDGFRB—nervous system—acquired immunodeficiency syndrome	6.68e-05	0.000399	CbGeAlD
Sunitinib—YES1—brain—acquired immunodeficiency syndrome	6.67e-05	0.000399	CbGeAlD
Sunitinib—EPHB6—lymph node—acquired immunodeficiency syndrome	6.66e-05	0.000398	CbGeAlD
Sunitinib—ABCC2—digestive system—acquired immunodeficiency syndrome	6.66e-05	0.000398	CbGeAlD
Sunitinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.62e-05	0.000304	CcSEcCtD
Sunitinib—STK10—brain—acquired immunodeficiency syndrome	6.6e-05	0.000395	CbGeAlD
Sunitinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.6e-05	0.000303	CcSEcCtD
Sunitinib—KIT—central nervous system—acquired immunodeficiency syndrome	6.58e-05	0.000394	CbGeAlD
Sunitinib—TAOK3—brain—acquired immunodeficiency syndrome	6.58e-05	0.000393	CbGeAlD
Sunitinib—ABCC4—blood—acquired immunodeficiency syndrome	6.55e-05	0.000392	CbGeAlD
Sunitinib—PDGFRA—brain—acquired immunodeficiency syndrome	6.54e-05	0.000391	CbGeAlD
Sunitinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	6.53e-05	0.0003	CcSEcCtD
Sunitinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.52e-05	0.000299	CcSEcCtD
Sunitinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.49e-05	0.000298	CcSEcCtD
Sunitinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.49e-05	0.000298	CcSEcCtD
Sunitinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.49e-05	0.000298	CcSEcCtD
Sunitinib—YES1—lymph node—acquired immunodeficiency syndrome	6.44e-05	0.000385	CbGeAlD
Sunitinib—Rash—Indinavir—acquired immunodeficiency syndrome	6.44e-05	0.000295	CcSEcCtD
Sunitinib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	6.43e-05	0.000384	CbGeAlD
Sunitinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.43e-05	0.000295	CcSEcCtD
Sunitinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.41e-05	0.000294	CcSEcCtD
Sunitinib—Headache—Indinavir—acquired immunodeficiency syndrome	6.39e-05	0.000293	CcSEcCtD
Sunitinib—STK10—lymph node—acquired immunodeficiency syndrome	6.38e-05	0.000382	CbGeAlD
Sunitinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.38e-05	0.000293	CcSEcCtD
Sunitinib—TAOK3—lymph node—acquired immunodeficiency syndrome	6.36e-05	0.00038	CbGeAlD
Sunitinib—ABCC2—blood—acquired immunodeficiency syndrome	6.34e-05	0.000379	CbGeAlD
Sunitinib—ABCC4—bone marrow—acquired immunodeficiency syndrome	6.34e-05	0.000379	CbGeAlD
Sunitinib—PDGFRA—lymph node—acquired immunodeficiency syndrome	6.32e-05	0.000378	CbGeAlD
Sunitinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.31e-05	0.00029	CcSEcCtD
Sunitinib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.29e-05	0.000288	CcSEcCtD
Sunitinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	6.22e-05	0.000372	CbGeAlD
Sunitinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.19e-05	0.000284	CcSEcCtD
Sunitinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.19e-05	0.000284	CcSEcCtD
Sunitinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.13e-05	0.000281	CcSEcCtD
Sunitinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.12e-05	0.000281	CcSEcCtD
Sunitinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.1e-05	0.00028	CcSEcCtD
Sunitinib—Rash—Efavirenz—acquired immunodeficiency syndrome	6.08e-05	0.000279	CcSEcCtD
Sunitinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.08e-05	0.000279	CcSEcCtD
Sunitinib—Nausea—Indinavir—acquired immunodeficiency syndrome	6.06e-05	0.000278	CcSEcCtD
Sunitinib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.05e-05	0.000278	CcSEcCtD
Sunitinib—Headache—Efavirenz—acquired immunodeficiency syndrome	6.04e-05	0.000277	CcSEcCtD
Sunitinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	6.04e-05	0.000277	CcSEcCtD
Sunitinib—KDR—brain—acquired immunodeficiency syndrome	5.9e-05	0.000353	CbGeAlD
Sunitinib—MAP2K5—brain—acquired immunodeficiency syndrome	5.9e-05	0.000353	CbGeAlD
Sunitinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.89e-05	0.00027	CcSEcCtD
Sunitinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.87e-05	0.000269	CcSEcCtD
Sunitinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.84e-05	0.000268	CcSEcCtD
Sunitinib—Rash—Delavirdine—acquired immunodeficiency syndrome	5.82e-05	0.000267	CcSEcCtD
Sunitinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.81e-05	0.000267	CcSEcCtD
Sunitinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	5.81e-05	0.000267	CcSEcCtD
Sunitinib—Headache—Delavirdine—acquired immunodeficiency syndrome	5.78e-05	0.000265	CcSEcCtD
Sunitinib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	5.77e-05	0.000265	CcSEcCtD
Sunitinib—CSF1R—brain—acquired immunodeficiency syndrome	5.76e-05	0.000344	CbGeAlD
Sunitinib—ABCC4—lung—acquired immunodeficiency syndrome	5.74e-05	0.000343	CbGeAlD
Sunitinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.73e-05	0.000263	CcSEcCtD
Sunitinib—KDR—lymph node—acquired immunodeficiency syndrome	5.7e-05	0.000341	CbGeAlD
Sunitinib—MAP2K5—lymph node—acquired immunodeficiency syndrome	5.7e-05	0.000341	CbGeAlD
Sunitinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.64e-05	0.000259	CcSEcCtD
Sunitinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.62e-05	0.000258	CcSEcCtD
Sunitinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.62e-05	0.000258	CcSEcCtD
Sunitinib—CSF1R—lymph node—acquired immunodeficiency syndrome	5.56e-05	0.000333	CbGeAlD
Sunitinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	5.54e-05	0.000254	CcSEcCtD
Sunitinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.48e-05	0.000251	CcSEcCtD
Sunitinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.43e-05	0.000249	CcSEcCtD
Sunitinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.43e-05	0.000249	CcSEcCtD
Sunitinib—Rash—Ritonavir—acquired immunodeficiency syndrome	5.38e-05	0.000247	CcSEcCtD
Sunitinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.38e-05	0.000247	CcSEcCtD
Sunitinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.36e-05	0.000246	CcSEcCtD
Sunitinib—Headache—Ritonavir—acquired immunodeficiency syndrome	5.35e-05	0.000245	CcSEcCtD
Sunitinib—ABCC4—nervous system—acquired immunodeficiency syndrome	5.32e-05	0.000318	CbGeAlD
Sunitinib—KIT—brain—acquired immunodeficiency syndrome	5.23e-05	0.000313	CbGeAlD
Sunitinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.22e-05	0.00024	CcSEcCtD
Sunitinib—KCNH2—blood—acquired immunodeficiency syndrome	5.2e-05	0.000311	CbGeAlD
Sunitinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.18e-05	0.000238	CcSEcCtD
Sunitinib—Rash—Saquinavir—acquired immunodeficiency syndrome	5.18e-05	0.000238	CcSEcCtD
Sunitinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.17e-05	0.000237	CcSEcCtD
Sunitinib—Headache—Saquinavir—acquired immunodeficiency syndrome	5.15e-05	0.000236	CcSEcCtD
Sunitinib—ABCC4—central nervous system—acquired immunodeficiency syndrome	5.12e-05	0.000306	CbGeAlD
Sunitinib—PDGFRB—brain—acquired immunodeficiency syndrome	5.11e-05	0.000305	CbGeAlD
Sunitinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.07e-05	0.000233	CcSEcCtD
Sunitinib—KIT—lymph node—acquired immunodeficiency syndrome	5.05e-05	0.000302	CbGeAlD
Sunitinib—KCNH2—bone marrow—acquired immunodeficiency syndrome	5.03e-05	0.000301	CbGeAlD
Sunitinib—KCNH2—spinal cord—acquired immunodeficiency syndrome	5.01e-05	0.000299	CbGeAlD
Sunitinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.98e-05	0.000229	CcSEcCtD
Sunitinib—Rash—Lamivudine—acquired immunodeficiency syndrome	4.94e-05	0.000227	CcSEcCtD
Sunitinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.94e-05	0.000226	CcSEcCtD
Sunitinib—PDGFRB—lymph node—acquired immunodeficiency syndrome	4.93e-05	0.000295	CbGeAlD
Sunitinib—Headache—Lamivudine—acquired immunodeficiency syndrome	4.91e-05	0.000225	CcSEcCtD
Sunitinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.88e-05	0.000224	CcSEcCtD
Sunitinib—KCNH2—vagina—acquired immunodeficiency syndrome	4.82e-05	0.000288	CbGeAlD
Sunitinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.65e-05	0.000214	CcSEcCtD
Sunitinib—ABCG2—blood—acquired immunodeficiency syndrome	4.62e-05	0.000276	CbGeAlD
Sunitinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	4.51e-05	0.000269	CbGeAlD
Sunitinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	4.47e-05	0.000268	CbGeAlD
Sunitinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	4.46e-05	0.000266	CbGeAlD
Sunitinib—CYP3A5—blood—acquired immunodeficiency syndrome	4.29e-05	0.000257	CbGeAlD
Sunitinib—ABCG2—vagina—acquired immunodeficiency syndrome	4.29e-05	0.000256	CbGeAlD
Sunitinib—KCNH2—nervous system—acquired immunodeficiency syndrome	4.22e-05	0.000252	CbGeAlD
Sunitinib—ABCC4—brain—acquired immunodeficiency syndrome	4.06e-05	0.000243	CbGeAlD
Sunitinib—KCNH2—central nervous system—acquired immunodeficiency syndrome	4.06e-05	0.000243	CbGeAlD
Sunitinib—ABCG2—lung—acquired immunodeficiency syndrome	4.05e-05	0.000242	CbGeAlD
Sunitinib—CYP3A5—vagina—acquired immunodeficiency syndrome	3.98e-05	0.000238	CbGeAlD
Sunitinib—ABCC4—lymph node—acquired immunodeficiency syndrome	3.93e-05	0.000235	CbGeAlD
Sunitinib—ABCC2—lymph node—acquired immunodeficiency syndrome	3.8e-05	0.000227	CbGeAlD
Sunitinib—CYP3A5—lung—acquired immunodeficiency syndrome	3.76e-05	0.000225	CbGeAlD
Sunitinib—ABCB1—retina—acquired immunodeficiency syndrome	3.41e-05	0.000204	CbGeAlD
Sunitinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	3.38e-05	0.000202	CbGeAlD
Sunitinib—KCNH2—brain—acquired immunodeficiency syndrome	3.23e-05	0.000193	CbGeAlD
Sunitinib—CYP3A4—blood—acquired immunodeficiency syndrome	3.22e-05	0.000193	CbGeAlD
Sunitinib—KCNH2—lymph node—acquired immunodeficiency syndrome	3.12e-05	0.000186	CbGeAlD
Sunitinib—ABCG2—brain—acquired immunodeficiency syndrome	2.87e-05	0.000172	CbGeAlD
Sunitinib—ABCG2—lymph node—acquired immunodeficiency syndrome	2.77e-05	0.000166	CbGeAlD
Sunitinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	2.62e-05	0.000156	CbGeAlD
Sunitinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	2.52e-05	0.000151	CbGeAlD
Sunitinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	2.42e-05	0.000145	CbGeAlD
Sunitinib—ABCB1—digestive system—acquired immunodeficiency syndrome	2.39e-05	0.000143	CbGeAlD
Sunitinib—ABCB1—blood—acquired immunodeficiency syndrome	2.28e-05	0.000136	CbGeAlD
Sunitinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	2.21e-05	0.000132	CbGeAlD
Sunitinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	2.2e-05	0.000131	CbGeAlD
Sunitinib—ABCB1—vagina—acquired immunodeficiency syndrome	2.11e-05	0.000126	CbGeAlD
Sunitinib—ABCB1—lung—acquired immunodeficiency syndrome	2e-05	0.00012	CbGeAlD
Sunitinib—ABCB1—nervous system—acquired immunodeficiency syndrome	1.85e-05	0.000111	CbGeAlD
Sunitinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	1.78e-05	0.000107	CbGeAlD
Sunitinib—ABCB1—brain—acquired immunodeficiency syndrome	1.41e-05	8.46e-05	CbGeAlD
Sunitinib—ABCB1—lymph node—acquired immunodeficiency syndrome	1.37e-05	8.17e-05	CbGeAlD
Sunitinib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.09e-06	6.05e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—IL2—acquired immunodeficiency syndrome	7.09e-06	6.05e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.08e-06	6.05e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—IL2—acquired immunodeficiency syndrome	7.07e-06	6.03e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	7.04e-06	6.01e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.98e-06	5.95e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	6.94e-06	5.92e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.91e-06	5.9e-05	CbGpPWpGaD
Sunitinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.87e-06	5.87e-05	CbGpPWpGaD
Sunitinib—FGFR1—Developmental Biology—TNF—acquired immunodeficiency syndrome	6.84e-06	5.84e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.84e-06	5.83e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.84e-06	5.83e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.82e-06	5.82e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.8e-06	5.8e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.8e-06	5.8e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.72e-06	5.73e-05	CbGpPWpGaD
Sunitinib—FYN—Axon guidance—IL6—acquired immunodeficiency syndrome	6.7e-06	5.72e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—CCR5—acquired immunodeficiency syndrome	6.69e-06	5.71e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Axon guidance—IL6—acquired immunodeficiency syndrome	6.67e-06	5.69e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—CCR5—acquired immunodeficiency syndrome	6.65e-06	5.68e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.62e-06	5.65e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Immune System—IL6—acquired immunodeficiency syndrome	6.58e-06	5.61e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.52e-06	5.57e-05	CbGpPWpGaD
Sunitinib—YES1—Developmental Biology—IL6—acquired immunodeficiency syndrome	6.52e-06	5.56e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Immune System—IL6—acquired immunodeficiency syndrome	6.51e-06	5.56e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.5e-06	5.54e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.5e-06	5.54e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.44e-06	5.5e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.43e-06	5.49e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.42e-06	5.48e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—IFNG—acquired immunodeficiency syndrome	6.42e-06	5.48e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.4e-06	5.46e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.38e-06	5.45e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.38e-06	5.45e-05	CbGpPWpGaD
Sunitinib—JAK2—Axon guidance—IL6—acquired immunodeficiency syndrome	6.37e-06	5.44e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—CCR5—acquired immunodeficiency syndrome	6.36e-06	5.43e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.34e-06	5.41e-05	CbGpPWpGaD
Sunitinib—CSNK1G2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.34e-06	5.41e-05	CbGpPWpGaD
Sunitinib—GRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.34e-06	5.41e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.33e-06	5.4e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.33e-06	5.4e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Developmental Biology—TNF—acquired immunodeficiency syndrome	6.3e-06	5.38e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.23e-06	5.32e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.23e-06	5.32e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—CD4—acquired immunodeficiency syndrome	6.2e-06	5.29e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	6.15e-06	5.25e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—IFNG—acquired immunodeficiency syndrome	6.09e-06	5.19e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.05e-06	5.17e-05	CbGpPWpGaD
Sunitinib—AXL—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.01e-06	5.13e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6e-06	5.12e-05	CbGpPWpGaD
Sunitinib—TYK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	6e-06	5.12e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.99e-06	5.11e-05	CbGpPWpGaD
Sunitinib—FYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.93e-06	5.06e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.91e-06	5.05e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IFNG—acquired immunodeficiency syndrome	5.91e-06	5.04e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.9e-06	5.03e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.9e-06	5.03e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—CD4—acquired immunodeficiency syndrome	5.88e-06	5.02e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.88e-06	5.01e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Immune System—IL6—acquired immunodeficiency syndrome	5.85e-06	4.99e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IFNG—acquired immunodeficiency syndrome	5.84e-06	4.98e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.8e-06	4.95e-05	CbGpPWpGaD
Sunitinib—YES1—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.76e-06	4.91e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.75e-06	4.9e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IFNG—acquired immunodeficiency syndrome	5.73e-06	4.89e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	5.73e-06	4.89e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Disease—IL6—acquired immunodeficiency syndrome	5.73e-06	4.89e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—CD4—acquired immunodeficiency syndrome	5.71e-06	4.87e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—IL2—acquired immunodeficiency syndrome	5.7e-06	4.87e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.7e-06	4.86e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.7e-06	4.86e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—CD4—acquired immunodeficiency syndrome	5.64e-06	4.81e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.63e-06	4.81e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	5.54e-06	4.72e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—CD4—acquired immunodeficiency syndrome	5.54e-06	4.72e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.53e-06	4.72e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.53e-06	4.72e-05	CbGpPWpGaD
Sunitinib—FGFR1—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.52e-06	4.71e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.51e-06	4.7e-05	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.5e-06	4.69e-05	CbGpPWpGaD
Sunitinib—IRAK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.46e-06	4.66e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.45e-06	4.65e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IFNG—acquired immunodeficiency syndrome	5.44e-06	4.64e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	5.43e-06	4.63e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—IL2—acquired immunodeficiency syndrome	5.41e-06	4.62e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.41e-06	4.62e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.39e-06	4.6e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.39e-06	4.6e-05	CbGpPWpGaD
Sunitinib—TBK1—Immune System—IL6—acquired immunodeficiency syndrome	5.37e-06	4.59e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.31e-06	4.53e-05	CbGpPWpGaD
Sunitinib—TYK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.3e-06	4.52e-05	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.29e-06	4.52e-05	CbGpPWpGaD
Sunitinib—CAMK2G—Immune System—IL6—acquired immunodeficiency syndrome	5.27e-06	4.5e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—CD4—acquired immunodeficiency syndrome	5.27e-06	4.5e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—CD4—acquired immunodeficiency syndrome	5.25e-06	4.48e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IL2—acquired immunodeficiency syndrome	5.25e-06	4.48e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	5.24e-06	4.47e-05	CbGpPWpGaD
Sunitinib—FGFR2—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.23e-06	4.47e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	5.23e-06	4.46e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—CD4—acquired immunodeficiency syndrome	5.2e-06	4.44e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.2e-06	4.44e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IL2—acquired immunodeficiency syndrome	5.19e-06	4.43e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.17e-06	4.41e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.17e-06	4.41e-05	CbGpPWpGaD
Sunitinib—MAP3K3—Immune System—IL6—acquired immunodeficiency syndrome	5.15e-06	4.4e-05	CbGpPWpGaD
Sunitinib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.14e-06	4.39e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.14e-06	4.39e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.13e-06	4.37e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.12e-06	4.37e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—CD4—acquired immunodeficiency syndrome	5.11e-06	4.36e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.1e-06	4.35e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.09e-06	4.35e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	5.09e-06	4.35e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IL2—acquired immunodeficiency syndrome	5.09e-06	4.35e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.09e-06	4.34e-05	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.03e-06	4.29e-05	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.03e-06	4.29e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IFNG—acquired immunodeficiency syndrome	5.01e-06	4.27e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.98e-06	4.25e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.94e-06	4.22e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	4.89e-06	4.17e-05	CbGpPWpGaD
Sunitinib—FGFR1—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.88e-06	4.16e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.88e-06	4.16e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.87e-06	4.16e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.87e-06	4.16e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.87e-06	4.15e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.86e-06	4.15e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—CD4—acquired immunodeficiency syndrome	4.85e-06	4.14e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	4.84e-06	4.13e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—CD4—acquired immunodeficiency syndrome	4.84e-06	4.13e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL2—acquired immunodeficiency syndrome	4.83e-06	4.12e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	4.82e-06	4.11e-05	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.8e-06	4.09e-05	CbGpPWpGaD
Sunitinib—IRAK4—Immune System—IL6—acquired immunodeficiency syndrome	4.79e-06	4.09e-05	CbGpPWpGaD
Sunitinib—FYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.78e-06	4.08e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.76e-06	4.06e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	4.72e-06	4.03e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—IFNG—acquired immunodeficiency syndrome	4.71e-06	4.02e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.7e-06	4.01e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IFNG—acquired immunodeficiency syndrome	4.69e-06	4e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.68e-06	4e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.66e-06	3.98e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Immune System—IL6—acquired immunodeficiency syndrome	4.66e-06	3.98e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Disease—IL6—acquired immunodeficiency syndrome	4.63e-06	3.95e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.56e-06	3.89e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—CD4—acquired immunodeficiency syndrome	4.55e-06	3.88e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.55e-06	3.88e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—CD4—acquired immunodeficiency syndrome	4.53e-06	3.86e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.52e-06	3.86e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.5e-06	3.84e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.5e-06	3.84e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.49e-06	3.84e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.49e-06	3.83e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IFNG—acquired immunodeficiency syndrome	4.48e-06	3.82e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—CD4—acquired immunodeficiency syndrome	4.47e-06	3.81e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.45e-06	3.8e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL2—acquired immunodeficiency syndrome	4.45e-06	3.8e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.38e-06	3.74e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	4.36e-06	3.72e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.36e-06	3.72e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.36e-06	3.72e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.36e-06	3.72e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	4.34e-06	3.71e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—CD4—acquired immunodeficiency syndrome	4.33e-06	3.69e-05	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—IL6—acquired immunodeficiency syndrome	4.27e-06	3.64e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.25e-06	3.63e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.25e-06	3.62e-05	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.22e-06	3.61e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.21e-06	3.59e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.2e-06	3.59e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—CD4—acquired immunodeficiency syndrome	4.2e-06	3.59e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL2—acquired immunodeficiency syndrome	4.19e-06	3.57e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—CD4—acquired immunodeficiency syndrome	4.18e-06	3.57e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—IL6—acquired immunodeficiency syndrome	4.17e-06	3.56e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL2—acquired immunodeficiency syndrome	4.16e-06	3.55e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—IL6—acquired immunodeficiency syndrome	4.15e-06	3.54e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.02e-06	3.43e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.01e-06	3.42e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—CD4—acquired immunodeficiency syndrome	3.99e-06	3.41e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL2—acquired immunodeficiency syndrome	3.98e-06	3.4e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.78e-06	3.23e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.75e-06	3.2e-05	CbGpPWpGaD
Sunitinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.72e-06	3.17e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.69e-06	3.15e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.5e-06	2.98e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.4e-06	2.9e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.38e-06	2.88e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.35e-06	2.86e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—IL6—acquired immunodeficiency syndrome	3.35e-06	2.86e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.29e-06	2.81e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.29e-06	2.81e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.24e-06	2.77e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	3.22e-06	2.75e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	3.19e-06	2.72e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—IL6—acquired immunodeficiency syndrome	3.18e-06	2.71e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.13e-06	2.67e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.12e-06	2.66e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IL6—acquired immunodeficiency syndrome	3.09e-06	2.63e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IL6—acquired immunodeficiency syndrome	3.05e-06	2.6e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.04e-06	2.59e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.01e-06	2.57e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	2.99e-06	2.55e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IL6—acquired immunodeficiency syndrome	2.99e-06	2.55e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.88e-06	2.46e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.86e-06	2.44e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—IL6—acquired immunodeficiency syndrome	2.85e-06	2.43e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL6—acquired immunodeficiency syndrome	2.84e-06	2.42e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	2.83e-06	2.42e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—IL6—acquired immunodeficiency syndrome	2.81e-06	2.4e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.81e-06	2.4e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—IL6—acquired immunodeficiency syndrome	2.76e-06	2.36e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.76e-06	2.36e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.71e-06	2.31e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.69e-06	2.3e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.68e-06	2.29e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.66e-06	2.27e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.64e-06	2.25e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—acquired immunodeficiency syndrome	2.62e-06	2.24e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	2.62e-06	2.23e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—acquired immunodeficiency syndrome	2.62e-06	2.23e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.57e-06	2.2e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.56e-06	2.19e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.56e-06	2.19e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.56e-06	2.18e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	2.55e-06	2.18e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.5e-06	2.13e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—acquired immunodeficiency syndrome	2.46e-06	2.1e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—acquired immunodeficiency syndrome	2.45e-06	2.09e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—acquired immunodeficiency syndrome	2.42e-06	2.06e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	2.36e-06	2.01e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—acquired immunodeficiency syndrome	2.34e-06	2e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	2.31e-06	1.97e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—acquired immunodeficiency syndrome	2.27e-06	1.94e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—acquired immunodeficiency syndrome	2.26e-06	1.93e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.17e-06	1.85e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—acquired immunodeficiency syndrome	2.16e-06	1.84e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.06e-06	1.75e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2e-06	1.7e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.97e-06	1.68e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.94e-06	1.65e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.94e-06	1.65e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.84e-06	1.57e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.83e-06	1.56e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.74e-06	1.49e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.69e-06	1.44e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.65e-06	1.41e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.59e-06	1.36e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.58e-06	1.35e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.51e-06	1.29e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.07e-06	9.15e-06	CbGpPWpGaD
